FFJ Portfolio – July 2024

This FFJ Portfolio - July 2024 report recaps my investment activity during the month. As disclosed in my FFJ Portfolio - June 2024 post, I have made multiple changes to the FFJ Portfolio because of changes to the tax treatment of capital gains in Canada. One of these changes entailed the sale of all shares [...]

By |August 1st, 2024|FFJ Portfolio Holdings|Comments Off on FFJ Portfolio – July 2024

CME Group Reports Strong Trading Volume

The Canadian federal government's proposed increase to the capital gains inclusion rate led us to revisit our estate plans. Based on guidance from our tax accountants, we liquidated all holdings within a specific investment account; I disclosed this in my June 11, 2024 FFJ Portfolio Adjustments Before Capital Gains Tax Changes Arrive post. CME Group [...]

By |July 29th, 2024|Equity Investing|Comments Off on CME Group Reports Strong Trading Volume

RTX Corporation Is No Longer On Sale

Often times, great companies suffer from temporary headwinds which may present buying opportunities. RTX Corporation (RTX) is a case in point. In 2023, RTX disclosed that its Pratt & Whitney business segment was experiencing significant challenges resulting from microscopic contaminants in a metal used in part of the Geared Turbofan (GTF) engines that power Airbus' [...]

By |July 29th, 2024|Equity Investing|Comments Off on RTX Corporation Is No Longer On Sale

Nasdaq Deleveraging Is Proceeding According To Plan

I last reviewed Nasdaq (NDAQ) in this April 26, 2024 post at which time the Q1 2024 results were the most current. Now that we have NDAQ's Q2 and YTD2024 results, I revisit this holding. Business Overview The best way to learn about NDAQ is to review its website. Part 1 Items 1 (Business) and [...]

By |July 28th, 2024|Equity Investing|Comments Off on Nasdaq Deleveraging Is Proceeding According To Plan

No Change In West Pharmaceutical’s Long Term Outlook

West Pharmaceutical's (WST) recent share price behavior has given rise to concern by some shareholders. After reviewing the recently released Q2 and YTD2024 results and the transcript of the Q2 earnings call with analysts, my opinion about WST's long term outlook is unchanged. WST remains a good long-term investment despite weaker than expected results and [...]

By |July 27th, 2024|Equity Investing|Comments Off on No Change In West Pharmaceutical’s Long Term Outlook

Thermo Fisher Is Richly Valued

  I last reviewed Thermo Fisher (TMO) in this February 2, 2024 post. In that post, I concluded that short term demand softness would likely pressure Thermo Fisher's valuation. With the recent release of Q2 and YTD2024 results and minor revisions to the FY2024 outlook, I revisit TMO. Business Overview I reviewed material presented at [...]

By |July 26th, 2024|Equity Investing|Comments Off on Thermo Fisher Is Richly Valued

I Would Avoid PPG Industries

  I would avoid PPG Industries, Inc. (PPG) and explain why I would do so in my guest post at Dividend Power. Investors relying on a steady stream of dividend income and who focus heavily on various dividend metrics will undoubtedly have a different opinion. Based on my goals, objectives, risk tolerance, and universe of [...]

By |July 26th, 2024|Equity Investing|Comments Off on I Would Avoid PPG Industries

I Can Not Justify Adding To My Moody’s Exposure

I can not justify adding to my Moody's (MCO) exposure because of its rich valuation. As a result, I must exercise patience if I want to acquire MCO shares to replace the shares our tax accountants recommended I sell in early June 2024 because of the changes in the taxation of capital gains introduced by [...]

By |July 26th, 2024|Equity Investing|Comments Off on I Can Not Justify Adding To My Moody’s Exposure

I Am Not Increasing My Fortive Exposure

With the recent release of FTV's Q2 and YTD2024 results and FY2024 outlook, I am taking this opportunity to determine if I should increase my Fortive (FTV) exposure. I last reviewed FTV, a Danaher (DHR) spin-off, in this February 1, 2024 post at which time it had just released its Q4 and FY2023 results and [...]

By |July 25th, 2024|Equity Investing|Comments Off on I Am Not Increasing My Fortive Exposure

I Have Increased My Visa Exposure

I have expressed my concern in several posts in what appears an element of irrational exuberance. This has made it difficult for me to identify attractively valued companies in which I wish to deploy surplus funds. On occasion, however, a company that appeals to me reaches an attractive or reasonable valuation. Enter Visa (V). I [...]

By |July 25th, 2024|Equity Investing|Comments Off on I Have Increased My Visa Exposure
Go to Top